Intravitreal injection of ranibizumab for the treatment of macular edema due to retinal vein occlusion

Objective To evaluate the clinical efficacy of intravitreal injection of ranibizumab (IVR) for the treatment of macular edema (CME) due to retinal vein occlusion. Methods The data of 72 eyes of 64 patients with retinal vein occlusion(RVO), from 2013 to 2014, were collected and analyzed retrospectively.All patients received IVR monthly for 3 months.According to the retinal ischemia area and retinal neovascularzation received retinal photocoagulation.The thickness of macular, visual acuity and IOP of every time point before and after IVR were recorded.The followed time was 6 months. Results The degree of CME of branch retinal vein occlcusion(BRVO) group was lower than that of central retinal vein occlusion(CRVO)group.After IVR injection the BCVA improved better(F=253.500, P<0.001). In BRVO group, the earlier the appointment time, the quicker visual recovery and the better CME improved (P<0.001). Conclusion The patients with CME from RVO receive monthly intravitreal ranibizumab injection early .The earlier treatment the greater improvements in BCVA. After 3 months the visual acuity is preserved a longer duration. Key words: Macular edema; Retinal vein occlusion; Ranibizumab; Introvitreal injection